Subscribe to this journal
Advanced Search
 array:23 [
  "pii" => "S2173574310700022"
  "issn" => "21735743"
  "doi" => "10.1016/S2173-5743(10)70002-2"
  "estado" => "S300"
  "fechaPublicacion" => "2010-01-01"
  "aid" => "70002"
  "copyright" => "Sociedad Española de Reumatología and Colegio Mexicano de Reumatología"
  "copyrightAnyo" => "2010"
  "documento" => "simple-article"
  "crossmark" => 0
  "subdocumento" => "edi"
  "cita" => "Reumatol Clin. 2010;6:3-4"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:2 [
    "total" => 502
    "formatos" => array:3 [
      "EPUB" => 37
      "HTML" => 328
      "PDF" => 137
    ]
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S2173574310700034"
    "issn" => "21735743"
    "doi" => "10.1016/S2173-5743(10)70003-4"
    "estado" => "S300"
    "fechaPublicacion" => "2010-01-01"
    "aid" => "70003"
    "copyright" => "Sociedad Española de Reumatología and Colegio Mexicano de Reumatología"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "fla"
    "cita" => "Reumatol Clin. 2010;6:5-10"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 3070
      "formatos" => array:3 [
        "EPUB" => 43
        "HTML" => 1499
        "PDF" => 1528
      ]
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "titulo" => "Hiperlaxity ligamentous (Beighton test) in the 8 to 12 years of age school population in the province of Granada"
      "tienePdf" => "en"
      "tieneTextoCompleto" => 0
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "5"
          "paginaFinal" => "10"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Hiperlaxitud ligamentosa (test de Beighton) en la población escolar de 8 a 12 aĩos de la provincia de Granada"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Félix Zurita Ortega, Luis Ruiz Rodríguez, Asunción Martínez Martínez, Manuel Fernández Sánchez, Concepción Rodríguez Paiz, Remedios López Liriaa"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "Félix"
              "apellidos" => "Zurita Ortega"
            ]
            1 => array:2 [
              "nombre" => "Luis"
              "apellidos" => "Ruiz Rodríguez"
            ]
            2 => array:2 [
              "nombre" => "Asunción"
              "apellidos" => "Martínez Martínez"
            ]
            3 => array:2 [
              "nombre" => "Manuel"
              "apellidos" => "Fernández Sánchez"
            ]
            4 => array:2 [
              "nombre" => "Concepción"
              "apellidos" => "Rodríguez Paiz"
            ]
            5 => array:2 [
              "nombre" => "Remedios"
              "apellidos" => "López Liriaa"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574310700034?idApp=UINPBA00004M"
    "url" => "/21735743/0000000600000001/v1_201305061603/S2173574310700034/v1_201305061603/en/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S2173574310700010"
    "issn" => "21735743"
    "doi" => "10.1016/S2173-5743(10)70001-0"
    "estado" => "S300"
    "fechaPublicacion" => "2010-01-01"
    "aid" => "70001"
    "copyright" => "Sociedad Española de Reumatología and Colegio Mexicano de Reumatología"
    "documento" => "simple-article"
    "crossmark" => 0
    "subdocumento" => "edi"
    "cita" => "Reumatol Clin. 2010;6:1-2"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 1368
      "formatos" => array:3 [
        "EPUB" => 39
        "HTML" => 933
        "PDF" => 396
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Systemic lupus erythematosus. “What do we know and where are we heading?”"
      "tienePdf" => "en"
      "tieneTextoCompleto" => 0
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "1"
          "paginaFinal" => "2"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Genética del lupus eritematoso generalizado. ¿Qué se sabe y a dónde se va?"
        ]
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Marta Eugenia Alarcón Riquelme"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Marta Eugenia"
              "apellidos" => "Alarcón Riquelme"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574310700010?idApp=UINPBA00004M"
    "url" => "/21735743/0000000600000001/v1_201305061603/S2173574310700010/v1_201305061603/en/main.assets"
  ]
  "en" => array:9 [
    "idiomaDefecto" => true
    "titulo" => "New drugs for rheumatoid arthritis: The industry point of view"
    "tieneTextoCompleto" => 0
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "3"
        "paginaFinal" => "4"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Stephen H. Polmar"
        "autores" => array:1 [
          0 => array:3 [
            "nombre" => "Stephen H."
            "apellidos" => "Polmar"
            "email" => array:1 [
              0 => "stephen@polmarconsulting.com"
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:1 [
            "entidad" => "Polmar Pharma Consulting, Woodbridge, Connecticut, USA"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Nuevos medicamentos contra la artritis reumatoide. El punto de vista de la industria"
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:2 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1."
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K.G. Saag"
                            1 => "G.G. Teng"
                            2 => "N.M. Patkar"
                            3 => "J. Anuntiyo"
                            4 => "C. Finney"
                            5 => "J.R. Curtis"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.23721"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2008"
                        "volumen" => "59"
                        "paginaInicial" => "762"
                        "paginaFinal" => "784"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18512708"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2."
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The PREMIER study: A multicenter, randomized, double-blind, clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "F.C. Breedveld"
                            1 => "M.H. Weisman"
                            2 => "A.F. Kavanaugh"
                            3 => "S.B. Cohen"
                            4 => "K. Pavelka"
                            5 => "R. Van Vollenhoven"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.21519"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2006"
                        "volumen" => "54"
                        "paginaInicial" => "26"
                        "paginaFinal" => "37"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16385520"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/21735743/0000000600000001/v1_201305061603/S2173574310700022/v1_201305061603/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "17335"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Editorial"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/21735743/0000000600000001/v1_201305061603/S2173574310700022/v1_201305061603/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574310700022?idApp=UINPBA00004M"
]
Share
January - February 2010 New drugs for rheumatoid arthritis: The industry point of view
Journal Information
Previous article | Next article
Vol. 6. Issue 1.
Pages 3-4 (January - February 2010)
Export reference
Share
Share
Print
Download PDF
More article options
Statistics
Vol. 6. Issue 1.
Pages 3-4 (January - February 2010)
DOI: 10.1016/S2173-5743(10)70002-2
Full text access
New drugs for rheumatoid arthritis: The industry point of view
Nuevos medicamentos contra la artritis reumatoide. El punto de vista de la industria
Visits
3538
Download PDF
Stephen H. Polmar
Polmar Pharma Consulting, Woodbridge, Connecticut, USA
This item has received
3538 Visits
Article information
Bibliography
Download PDF
Statistics
Full text is only aviable in PDF
References
[1.]
K.G. Saag, G.G. Teng, N.M. Patkar, J. Anuntiyo, C. Finney, J.R. Curtis, et al.
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
Arthritis Rheum, 59 (2008), pp. 762-784
http://dx.doi.org/10.1002/art.23721 | Medline
[2.]
F.C. Breedveld, M.H. Weisman, A.F. Kavanaugh, S.B. Cohen, K. Pavelka, R. Van Vollenhoven, et al.
The PREMIER study: A multicenter, randomized, double-blind, clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Arthritis Rheum, 54 (2006), pp. 26-37
http://dx.doi.org/10.1002/art.21519 | Medline
Copyright © 2010. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología

Subscribe to our newsletter

Recommended
articles
Practical aspects of biological throught levels and...
Reumatol Clin. 2020;16P2:378-85
Publish in
Reumatología Clínica
Free access articles
Efficacy of psychological interventions to reduce anxiety...
Reumatol Clin. 2024;20:440-51
Controversy about the use and financing of SYSADOA for...
Reumatol Clin. 2024;20:416-22
Real-world apremilast use in biologic-naïve psoriatic...
Reumatol Clin. 2024;20:24-31
Download PDF
Idiomas
Reumatología Clínica (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?